Metrics to compare | 203400 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship203400PeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.8x | −11.6x | −0.4x | |
PEG Ratio | −0.04 | −0.50 | 0.00 | |
Price/Book | 1.2x | 2.6x | 2.6x | |
Price / LTM Sales | 70.6x | 8.4x | 3.1x | |
Upside (Analyst Target) | - | 230.0% | 48.3% | |
Fair Value Upside | Unlock | 12.5% | 6.1% | Unlock |
ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various respiratory viruses. It is also developing ABN701 for SEBI infectious diseases; and ABN 901, ABN 902, and ABN 903 for infectious diseases related to biological disasters. Abion Inc. was founded in 2007 and is based in Seoul, South Korea.